All News
#ACRbest Abstracts – Day 3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
Read Article
#CAR T cells #ACR23
🔥Back to back Sessions on one of the most avidly researched area in Rheum!
💡Check out these slides to understand:
☣️Toxicities and Limitations of CAR T therapy
🆕 Novel CAR designs
⚡️CAR cell sources
❓Research Questions to ponder!
#ACRambassador https://t.co/6sOn4rjqY3
debaditya_roy ( View Tweet)
Toxicities and limitations of CAR therapy:
the other side of its incredibly exciting, boundless potential
@Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC
David Liew drdavidliew ( View Tweet)
Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor.
46% flared
Seropositive- OR 2.0
NO association with mortality
-ICIs are safe to use in RA
-Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China
20% met def’n- diff trajectories
37% flare
1/6 got damage in f/u
Some tapered Rx
How to identify safe to d/c Rx?
2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz
Janet Pope ( View Tweet)
Are all ICI-IA irAEs the same?
@cappelliMD @jhrheumatology presented lovely work: latent class analysis on her cohort data
She found two phenotypes - one with more persistent symptoms, & potentially a start in stratifying irAE therapy going forward.
#ACR23 ABST2513 @RheumNow https://t.co/roW00KwbVZ
David Liew drdavidliew ( View Tweet)
Patella tendon characteristics with USG - thickness, cross sectional area and stiffness measures with shear wave elastography
In pts with or without knee pain
@rheumnow #ACR23 52 pts Pain didnt correralate with thick ess and cross sectional area but did correlate with stiffness https://t.co/q3ZPG1l2n2
Bella Mehta bella_mehta ( View Tweet)
Plenary Abs #2425: Pregnancies among vasculitis pts - higher frequency of spontaneous abortion and preterm delivery. Risk of maternal complications associated with vasculitis were observed to vary by vessel size and parity. #ACR23 https://t.co/qLcpNapcjg @rheumnow https://t.co/sk3dhySVfP
Dr. Rachel Tate ( View Tweet)
LNK01001 12 mg or 24 mg BID to 24 weeks in moderate to severe RA achieved ACR 20 (91.1%, 90.7% respectively), were generally safe, well tolerated with most TEAEs being mild to moderate. Effect seen in Week 1. Wu C, Late breaking Abst#L09 #ACR23 @RheumNow https://t.co/M29LYtEs9I
Dr. Antoni Chan ( View Tweet)
AutoAb and irAE?? Really only associated for thyroid dysfunction. For ICI-IA we need different bio markers #ACR23 https://t.co/Fc24y8TzJv
Laura Cappelli ( View Tweet)
Congratulations to Mount Sinai medical student and mentee Celestine He, on being awarded a Rheumatology Research Foundation Medical Student Preceptorship Award. Very proud of you and your excellent work! 👏🏻👏🏻👏🏻
#ACR23 @celestinejhe @MSRheumatology @IcahnMountSinai https://t.co/F078eSnL9p
Chrisanna Dobrowolski ( View Tweet)
Our collaborative study on nirmatrelvir-ritonavir (Paxlovid) virologic rebound is out in @AnnalsofIM @DrJLi @zach_wallace_md
-Paxlovid: 21% with rebound vs. 2% in untreated (OR 10)
https://t.co/RRDxerGdBy
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
US adults with #gout had higher 10-year all-cause mortality rates than those without
Premature mortality in gout
➡️Has not improved over time despite improved survival in the general population
➡️Worse among women
➡️Worse among Black individuals
#ACR23
👉🏽https://t.co/NDCIhKfCNL https://t.co/uKCswHKU0n
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Hanging w a super star ⭐️ @CCalabreseDO https://t.co/yDcAMAr24V
Leonard Calabrese LCalabreseDO ( View Tweet)
It's the fab @AurelieRheumo 🎉 https://t.co/ywp9uPC5yl
Beth ( View Tweet)
https://t.co/ft1wNmMxGx
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
So great to see posters back at #ACR23 and interactions of #students and #mentors which can be career shaping. Data from #Alberta with a nearly 3K survey on #cannabis use in Pts with #rheumatic diseases studying the use as #Rx and #recreational @RheumNow #979, 980 https://t.co/xbVcK5HuRS
Janet Pope ( View Tweet)
#Exercise reduces #pain in knee #osteoarthritis
▶️Improvement at weeks 6 & 12, sustained at week 18
#ACR23 poster 1990
👉🏽https://t.co/y4quoWG5Hi
by @ProfDeepakKumar et al https://t.co/zbf05FCLZ9
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
#ACR23 Abs #L07 data do not support tapering of TNFi treatment among RA patients in sustained remission in 3 year study. https://t.co/d0ZBWDKZlB https://t.co/EdllyGUT1y
Dr. Rachel Tate ( View Tweet)
Anyone have any insight on the number of missing virtual posters #ACR23 ? Is it simply that people did not submit one by the deadline?
Richard Conway ( View Tweet)